{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Jcvillasboas.jpg|frameless|upright=0.3|center]]
|<big>[[User:Jcvillasboas|J.C. Villasboas Bisneto, MD]]<br>Rochester, MN</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[http://www.esmo.org/ ESMO]==
*'''2017:''' Dreyling et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Newly-Diagnosed-and-Relapsed-Mantle-Cell-Lymphoma Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
===Older===
*'''2014:''' Dreyling et al. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdu264 Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/25210087 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf NCCN Guidelines - B-Cell Lymphomas]

=First-line therapy, pre-phase=
==CVP {{#subobject:1c1228|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CVP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone
===Regimen {{#subobject:bd8596|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisolone (Millipred)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''One cycle'''
====Subsequent treatment====
*[[#R-DHAC|R-DHAC]] x 4 or [[#R-DHAOx|R-DHAOx]] x 4 or [[#R-DHAP|R-DHAP]] x 4

===References===
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1701769/suppl_file/nejmoa1701769_appendix.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

=First-line therapy, randomized data=

==BR {{#subobject:b7779c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab
<br>RB: '''<u>R</u>'''ituximab, '''<u>B</u>'''endamustine
===Variant #1, 3 cycles {{#subobject:bae89a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13929/full Armand et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*SD or better: [[#R-HiDAC|R-HiDAC]]

===Variant #2, 6 cycles {{#subobject:68b17c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext Rummel et al. 2013 (StiL NHL1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#1a9850"|Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318240/ Chen et al. 2016 (SWOG S1106)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#R-Hyper-CVAD.2FR-MA|R-Hyper-CVAD/R-MA]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*Antiemetics, antipyretics, and antibiotics according to local standard of care
*Prophylactic use of [[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] allowed according [http://jop.ascopubs.org/content/2/4/196.full ASCO guidelines] (2006)

'''28-day cycle for up to 6 cycles'''
====Subsequent treatment====
*SWOG S1106, responders: [[#BEAM.2C_then_auto_HSCT|BEAM, then auto HSCT]] or [[#CBV.2C_then_auto_HSCT|CBV, then auto HSCT]] or cyclophosphamide, etoposide, TBI, then auto HSCT, depending on age and center

===Variant #3, 8 cycles {{#subobject:1483a3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#R-CHOP|R-CHOP]]<br> 2. [[#R-CVP|R-CVP]]
|style="background-color:#1a9850"|Superior PFS (*)
|-
|}
''Reported efficacy is based on the 2017 update.''
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*Antiemetics, antipyretics, and antibiotics according to local standard of care
*Prophylactic use of [[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] allowed according [http://jop.ascopubs.org/content/2/4/196.full ASCO guidelines] (2006)

'''28-day cycle for up to 8 cycles'''

===References===
<!-- 
# Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke and Wolfram Brugger. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). 2009 ASH Annual Meeting abstract 405. [http://www.bloodjournal.org/content/114/22/405 link to abstract]
# Mathias J. Rummel, Norbert Niederle, Georg Maschmeyer, Andre G. Banat, Ulrich von Gruenhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz A. Duerk, Harald Ballo, Martina Stauch, Juergen Barth, Axel Hinke, Wolfram Brugger, Study Group Indolent Lymphomas (StiL). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. 2012 ASCO Annual Meeting abstract 3. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview==abst_detail_view&confID==114&abstractID==95807 link to abstract] [http://www.ascopost.com/issues/july-1-2012/german-study-finds-bendamustine-improves-progression-free-survival-in-patients-with-non-hodgkin-lymphoma.aspx ASCO Post article] [http://www.asco.org/ASCOv2/MultiMedia/Virtual%20Meeting?&vmview==vm_session_presentations_view&confID==114&sessionID==4807 ASCO plenary session video] -->
# '''StiL NHL1:''' Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; on behalf of the Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23433739 PubMed]
## '''Update: Abstract:''' Mathias J. Rummel, MD, Georg Maschmeyer, MD, Arnold Ganser, Andrea Heider, PhD, Ulrich von Grünhagen, MD, PhD5, Christoph Losem, Gerhard Heil, MD, Manfred Welslau, Christina Balser, MD, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz Dürk, MD, Hans Peter Böck, Martina Beate Stauch, MD, Jürgen Barth, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. Blood 2014 124:4407. [http://www.bloodjournal.org/content/124/21/4407 link to abstract]
<!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] -->
# '''BRIGHT:''' Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://www.bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed]
## '''Update: Abstract:''' Ian Flinn, Richard van der Jagt, Julie E. Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, and John M. Burke. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. Journal of Clinical Oncology 2017 35:15_suppl, 7500-7500 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7500 link to abstract]
# Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED. A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr;173(1):89-95. Epub 2016 Jan 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13929/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26729345 PubMed]
# '''SWOG S1106:''' Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017 Mar;176(5):759-769. Epub 2016 Dec 19. [https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14480 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318240/ link to PMC article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27992063 PubMed]

==CHOP {{#subobject:d6600|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Regimen {{#subobject:cc7182|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/9/1984.long Lenz et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#d73027"|Inferior ORR
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.22093/full Nickenig et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|[[#MCP|MCP]]
|style="background-color:#d9ef8b"|Might have superior ORR
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 6 to 8 cycles'''

===References===
# Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24. [http://jco.ascopubs.org/content/23/9/1984.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15668467 PubMed]
# Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.22093/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16878325 PubMed]

==FC {{#subobject:c122ba|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FC: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide

===Regimen {{#subobject:0d3d4b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ Rule et al. 2015 (CRUK-UCL-MCLIII)]
|style="background-color:#1a9851"|Phase III (C)
|[[#FCR|FCR]]
|style="background-color:#d73027"|Inferior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 3
**Patients intolerant of the oral route received 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> PO once per day on days 1 to 3
**Patients intolerant of the oral route received 250 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*PJP prophylaxis was mandatory

'''28-day cycle for up to 8 cycles'''

===References===
# Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. [http://www.haematologica.org/content/101/2/235.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26611473 PubMed]

==FCR {{#subobject:957676|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FCR: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab
<br> R-FC: '''<u>R</u>'''ituximab, '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide
===Variant #1, 30/250/375 {{#subobject:839caa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 Kluin-Nelemans et al. 2012 (MCLelderly)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#d73027"|Inferior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> (maximum dose: 750 mg/m<sup>2</sup>) IV once on day 1

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*Responders: [[#Rituximab_monotherapy|Rituximab]] versus [[#Interferon_alfa_monotherapy|interferon alfa]] maintenance

===Variant #2, 40/25/375 {{#subobject:9ecbf7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ Rule et al. 2015 (CRUK-UCL-MCLIII)]
|style="background-color:#1a9851"|Phase III (E)
|[[#FC|FC]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 3
**Patients intolerant of the oral route received 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> PO once per day on days 1 to 3
**Patients intolerant of the oral route received 250 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*PJP prophylaxis was mandatory

'''28-day cycle for up to 8 cycles'''
===References===
# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22873532 PubMed]
# Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. [http://www.haematologica.org/content/101/2/235.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26611473 PubMed]

==MCP {{#subobject:a84c0e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MCP: '''<u>M</u>'''itoxantrone, '''<u>C</u>'''hlorambucil, '''<u>P</u>'''rednisolone

===Regimen {{#subobject:56b74a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.22093/full Nickenig et al. 2006]
|style="background-color:#1a9851"|Phase III (E)
|[[#CHOP|CHOP]]
|style="background-color:#fee08b"|Might have inferior ORR
|-
|}
''Note: the chlorambucil dose is written in the reference as "3 x 3 mg/m<sup>2</sup>"; total dose per day is 9 mg/m<sup>2</sup>.''
====Chemotherapy====
*[[Mitoxantrone (Novantrone)]] 8 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Chlorambucil (Leukeran)]] 3 mg/m<sup>2</sup> PO three times per day on days 1 to 5
*[[Prednisone (Sterapred)]] 25 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''28-day cycle for 6 to 8 cycles'''

===References===
# Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.22093/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16878325 PubMed]

==R-CHOP {{#subobject:ca52ab|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Example orders===
*[[Example orders for R-CHOP in lymphoma]]
===Variant #1, prednisone 100 mg {{#subobject:f5db72|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 Kluin-Nelemans et al. 2012 (MCLelderly)]
|style="background-color:#1a9851"|Phase III (C)
|[[#FCR|R-FC]]
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR|BR]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*Antiemetics, antipyretics, and antibiotics per local standard of care
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] "according to the [http://jco.ascopubs.org/content/18/20/3558.full American Society of Clinical Oncology guidelines]"

'''21-day cycle for up to 8 cycles'''
====Subsequent treatment====
*MCLelderly: [[#Rituximab_monotherapy|Rituximab]] versus [[#Interferon_alfa_monotherapy|interferon alfa]] maintenance

===Variant #2, prednisone 100 mg/m<sup>2</sup> {{#subobject:6eca9e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/9/1984.long Lenz et al. 2005]
|style="background-color:#1a9851"|Phase III (E)
|[[#CHOP|CHOP]]
|style="background-color:#1a9850"|Superior ORR
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1412096 Robak et al. 2015 (LYM-3002)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VR-CAP|VR-CAP]]
|style="background-color:#d73027"|Inferior OS (*)
|-
|}
''Note the slight difference between the two protocols in terms of rituximab timing. Reported efficacy for LYM-3002 is based on the 2018 update.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day -1 ('''Lenz et al. 2005''') or day 1 ('''LYM-3002''')
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 6 cycles (Lenz et al. 2005) or up to 8 cycles (LYM-3002)'''

===Variant #3, uncapped vincristine {{#subobject:360915|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext Rummel et al. 2013 (StiL NHL1)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR|BR]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle up to maximum of 6 cycles'''

===Variant #4, 3 cycles {{#subobject:c7982b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07498.x/full Van 't Veer et al. 2008 (HOVON 45)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Patients with at least PR: [[#R-HiDAC|R-HiDAC]]

===Variant #5, 3 cycles, rituximab in cycle 3 only {{#subobject:53c52a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/121/1/48.full Delarue et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycles 1 & 2: none
**Cycle 3: 375 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

====CNS prophylaxis====
''Intrathecal prophylaxis with the following was given per physician discretion; no timeframe or total number of doses is described:''
*[[Methotrexate (MTX)]] 15 mg IT
*[[Cytarabine (Cytosar)]] 40 mg IT
*Corticosteroids

'''21-day cycle for up to 3 cycles'''
====Subsequent treatment====
*[[#R-DHAP|R-DHAP]]; patients who progress after first 2 cycles go directly to R-DHAP

===Variant #6, 4 cycles {{#subobject:b10fa8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732008/ Smith et al. 2012 (ECOG E1499)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Ibritumomab_tiuxetan_monotherapy|Ibritumomab tiuxetan consolidation]], in 4 to 8 weeks

===References===
# Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24. [http://jco.ascopubs.org/content/23/9/1984.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15668467 PubMed]
# Van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL. High-dose Ara-C and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009 Feb;144(4):524-30. Epub 2008 Nov 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07498.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19036081 PubMed]
# Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O; for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013 Jan 3;121(1):48-53. Epub 2012 Jun 20. [http://www.bloodjournal.org/content/121/1/48.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22718839 PubMed]
# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22873532 PubMed]
<!-- Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006; the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2007; and the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011. -->
# Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012 Sep 1;30(25):3119-26. Epub 2012 Jul 30. [http://jco.ascopubs.org/content/30/25/3119.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732008/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22851557 PubMed]
## '''Update:''' Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, Advani RH, Forero-Torres A, Horning SJ, Kahl BS. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia. 2017 Feb;31(2):517-519. Epub 2016 Oct 26. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288271/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27780968 PubMed]
<!-- 
# Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke and Wolfram Brugger. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). 2009 ASH Annual Meeting abstract 405. [https://ash.confex.com/ash/2009/webprogram/Paper20178.html link to abstract]
# Mathias J. Rummel, Norbert Niederle, Georg Maschmeyer, Andre G. Banat, Ulrich von Gruenhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz A. Duerk, Harald Ballo, Martina Stauch, Juergen Barth, Axel Hinke, Wolfram Brugger, Study Group Indolent Lymphomas (StiL). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. 2012 ASCO Annual Meeting abstract 3. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview==abst_detail_view&confID==114&abstractID==95807 link to abstract] [http://www.ascopost.com/issues/july-1-2012/german-study-finds-bendamustine-improves-progression-free-survival-in-patients-with-non-hodgkin-lymphoma.aspx ASCO Post article] [http://www.asco.org/ASCOv2/MultiMedia/Virtual%20Meeting?&vmview==vm_session_presentations_view&confID==114&sessionID==4807 ASCO plenary session video] -->
# '''StiL NHL1:''' Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; on behalf of the Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961763-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23433739 PubMed]
## '''Update: Abstract:''' Mathias J. Rummel, MD, Georg Maschmeyer, MD, Arnold Ganser, Andrea Heider, PhD, Ulrich von Grünhagen, MD, PhD5, Christoph Losem, Gerhard Heil, MD, Manfred Welslau, Christina Balser, MD, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz Dürk, MD, Hans Peter Böck, Martina Beate Stauch, MD, Jürgen Barth, Wolfgang Blau, MD, Alexander Burchardt, MD, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. Blood 2014 124:4407. [http://www.bloodjournal.org/content/124/21/4407 link to abstract]
<!-- # Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] -->
# '''BRIGHT:''' Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://www.bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed]
## '''Update: Abstract:''' Ian Flinn, Richard van der Jagt, Julie E. Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, and John M. Burke. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. Journal of Clinical Oncology 2017 35:15_suppl, 7500-7500 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7500 link to abstract]
<!-- # '''Abstract:''' Franco Cavalli, Brendan Rooney, Lixia Pei, Helgi Van De Velde, Tadeusz Robak, on behalf of the LYM-3002 Investigators. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). 2014 ASCO Annual Meeting abstract 8500. [http://meetinglibrary.asco.org/content/129206-144 link to abstract] -->
# '''LYM-3002:''' Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; the LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015 Mar 5;372(10):944-953. [https://www.nejm.org/doi/full/10.1056/NEJMoa1412096 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25738670 PubMed]
## '''Update:''' Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Nov;19(11):1449-58. Epub 2018 Oct 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30685-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30348538 PubMed]
# '''MCL Younger:''' Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75. Epub 2016 Jun 14. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00739-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27313086 PubMed]

==R-CHOP-14 {{#subobject:50294c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOP-14: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone every '''<u>14</u>''' days

===Regimen {{#subobject:4b4e17|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#R-DHAC|R-DHAC]] x 4 or [[#R-DHAOx|R-DHAOx]] x 4 or [[#R-DHAP|R-DHAP]] x 4, with PR
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisolone (Millipred)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*Not specified

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#R-BEAM.2C_then_auto_HSCT|R-BEAM with autologous HSCT]]

===References===
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1701769/suppl_file/nejmoa1701769_appendix.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

==R-CHOP/R-DHAP {{#subobject:989434|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOP/R-DHAP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone alternating with '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:dea6ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00739-X/fulltext Hermine et al. 2016 (MCL Younger)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#91cf60"|Seems to have superior TTTF
|-
|}
''Note: dosing details were not available in the abstract. The doses here are similar to the regimen of R-CHOP followed by R-DHAP by Delarue et al. 2012; please see original paper for actual dosing details.''
====Chemotherapy, R-CHOP portion====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for up to 3 cycles, alternating with R-DHAP'''

====Chemotherapy, R-DHAP portion====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours x 2 doses on day 2 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

'''21-day cycle for 3 cycles, alternating with R-CHOP'''
====Subsequent treatment====
*High-dose therapy with autologous hematopoietic stem cell transplant

===References===
# '''MCL Younger:''' Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75. Epub 2016 Jun 14. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00739-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27313086 PubMed]

==R-CVP {{#subobject:d4a808|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CVP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone

===Regimen {{#subobject:8c0109|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ Flinn et al. 2014 (BRIGHT)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR|BR]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> or 1000 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*Antiemetics, antipyretics, and antibiotics per local standard of care
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] "according to the [http://jco.ascopubs.org/content/18/20/3558.full American Society of Clinical Oncology guidelines]"

'''21-day cycle for up to 8 cycles'''

===References===
<!-- # '''Abstract:''' Ian Flinn et al. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. 2012 ASH Annual Meeting abstract 902. [https://ash.confex.com/ash/2012/webprogram/Paper51442.html link to abstract] -->
# '''BRIGHT:''' Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. [http://www.bloodjournal.org/content/123/19/2944.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24591201 PubMed]

==R-Hyper-CVAD/R-MA {{#subobject:a76238|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-Hyper-CVAD/R-MA: '''<u>R</u>'''ituximab, '''<u>Hyper</u>'''fractionated '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone alternating with '''<u>R</u>'''ituximab, '''<u>M</u>'''ethotrexate, '''<u>A</u>'''ra-C (Cytarabine)
===Regimen {{#subobject:abb9f1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/28/7013.long Romaguera et al. 2005]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.23880/full Wang et al. 2008]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2011.08958.x Merli et al. 2012]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660082/ Bernstein et al. 2013 (SWOG 0213)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318240/ Chen et al. 2016 (SWOG S1106)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#BR|BR]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: Romaguera et al. 2005 had slightly different doxorubicin dosages in the text vs. table 1. Bernstein et al. 2013 use the original protocol as specified in Romaguera et al. 2005.''
====Part A (cycles 1, 3, 5, 7)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1, '''given first'''
**Patients with peripheral blood involvement could have the cycle 1 dose of rituximab delayed or omitted by clinician discretion
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV over 3 hours every 12 hours x 6 doses on days 2 to 4, '''given second'''
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 5 & 12, '''given 12 hours after the last dose of [[Cyclophosphamide (Cytoxan)]] on day 5'''
*[[Doxorubicin (Adriamycin)]] 16.6 to 16.7 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 5 (total dose per cycle: 49.8 to 50.1 mg/m<sup>2</sup>) 
*[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 2 to 5, 12 to 15

====Supportive medications====
*[[Mesna (Mesnex)]] 600 mg/m<sup>2</sup>/day IV continuous infusion over 76 hours, started on day 2, 1 hour before [[Cyclophosphamide (Cytoxan)]] and completed 12 hours after the last dose of [[Cyclophosphamide (Cytoxan)]] 
**"Over 76 hours" is not exactly specified in Romaguera et al. 2005; Wang et al. 2008. It is based on the assumption that "completed 12 hours after the last dose of cyclophosphamide" means that it would finish 12 hours after the last dose of cyclophosphamide completes.
''All growth factors and antibiotics given for 10 days, starting 24 to 36 hours after doxorubicin infusion is complete''
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day 
*[[Valacyclovir (Valtrex)]] 500 mg PO once per day
*[[Fluconazole (Diflucan)]] 100 mg PO once per day
*[[Levofloxacin (Levaquin)]] 500 mg PO once per day or [[Ciprofloxacin (Cipro)]] 500 mg PO twice per day
*[[:Category:Erythrocyte_growth_factors|Erythropoietin]] was permitted throughout therapy

'''21-day cycles, alternating every 21 days with Part B, for a total of 4 cycles of Part A and 4 cycles of Part B'''

====Part B (cycles 2, 4, 6, 8)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 2, then 800 mg/m<sup>2</sup> IV over 22 hours (total dose per cycle: 1000 mg/m<sup>2</sup>)
**Urine alkalinized to pH of 6.8 or more prior to the start of methotrexate and kept within that range until methotrexate is cleared
**Patients with a Cr greater than 1.5 mg/dL received a 50% reduced dose of methotrexate 
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV over 2 hours every 12 hours on days 3 & 4 (4 doses total)
**Dose reduced to 1000 mg/m<sup>2</sup> for patients greater than 60 years old or with Cr greater than 1.5 mg/dL

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 50 mg PO once 12 hours after [[Methotrexate (MTX)]] is complete, then 15 mg PO Q6H x 8 doses. If serum methotrexate level at 24 hours is greater than 1000 nmol/L or at 48 hours is greater than 100 nmol/L, dose is increased to 100 mg IV Q3H.
*[[Prednisolone (Millipred) | Prednisolone]] 1% ophthalmic solution 2 drops in each eye 4 times per day on days 3 to 9 was started on the day of the start of [[Cytarabine (Cytosar)]] infusion and was continued for 7 days to prevent chemical conjunctivitis.
''The starting day of the following medications was not specified. All medications are given for 10 days.''
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day 
*[[Valacyclovir (Valtrex)]] 500 mg PO once per day
*[[Fluconazole (Diflucan)]] 100 mg PO once per day
*[[Levofloxacin (Levaquin)]] 500 mg PO once per day or [[Ciprofloxacin (Cipro)]] 500 mg PO twice per day
*[[:Category:Erythrocyte_growth_factors|Erythropoietin]] was permitted throughout therapy

'''21-day cycles, alternating every 21 days with Part A, for a total of 4 cycles of Part A and 4 cycles of Part B'''
====Subsequent treatment====
*Merli et al. 2012, responders: autologous HSCT (regimen not specified) 

===References===
# Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 1;23(28):7013-23. Epub 2005 Sep 6. [http://jco.ascopubs.org/content/23/28/7013.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16145068 PubMed]
## '''Update:''' Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul;150(2):200-8. Epub 2010 May 26. Review. Erratum in: Br J Haematol.n 2010 Oct;151(1):111. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08228.x/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20528872 PubMed]
## '''Update:''' Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan;172(1):80-8. Epub 2015 Dec 9. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13796/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471614/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26648336 PubMed]
# Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15;113(10):2734-41.[https://onlinelibrary.wiley.com/doi/10.1002/cncr.23880/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18973182 PubMed]
# Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F, Di Renzo N, Angrilli F, Carella AM, Capodanno I, Barbolini E, Galimberti S, Federico M. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012 Feb;156(3):346-53. Epub 2011 Dec 7. [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2011.08958.x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22145911 PubMed]
# '''SWOG S0213:''' Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013 Jun;24(6):1587-93. Epub 2013 Mar 15. [http://annonc.oxfordjournals.org/content/24/6/1587.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660082/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23504948 PubMed]
# '''SWOG S1106:''' Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017 Mar;176(5):759-769. Epub 2016 Dec 19. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318240/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27992063 PubMed]

==VR-CAP {{#subobject:de09c8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VR-CAP: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisone

===Regimen {{#subobject:8ab61|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1412096 Robak et al. 2015 (LYM-3002)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|}
''Note: reported efficacy is based on the 2018 update.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11, '''given first''' 
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for up to 8 cycles'''

===References===
<!-- # '''Abstract:''' Franco Cavalli, Brendan Rooney, Lixia Pei, Helgi Van De Velde, Tadeusz Robak, on behalf of the LYM-3002 Investigators. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). 2014 ASCO Annual Meeting abstract 8500. [http://meetinglibrary.asco.org/content/129206-144 link to abstract] -->
# '''LYM-3002:''' Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; the LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015 Mar 5;372(10):944-953. [https://www.nejm.org/doi/full/10.1056/NEJMoa1412096 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25738670 PubMed]
## '''Update:''' Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Nov;19(11):1449-58. Epub 2018 Oct 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30685-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30348538 PubMed]

=First-line therapy, non-randomized or retrospective data=

==Chlorambucil & Rituximab {{#subobject:f5fb55|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:e9fbd5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2010.534518 Sachanas et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 10 mg PO once per day on days 2 to 11 of cycles 1 to 8, then once per day on days 1 to 10 of cycles 9 to 12
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 of cycles 1 to 8

'''28-day cycle for 12 cycles'''
====Subsequent treatment====
*PR/CR: [[#Rituximab_monotherapy|Rituximab maintenance]]

===References===
# Sachanas S, Pangalis GA, Vassilakopoulos TP, Korkolopoulou P, Kontopidou FN, Athanasoulia M, Yiakoumis X, Kalpadakis C, Georgiou G, Masouridis S, Moschogiannis M, Tsirkinidis P, Pappis V, Kokoris SI, Siakantaris MP, Panayiotidis P, Angelopoulou MK. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma. 2011 Mar;52(3):387-93. Epub 2010 Dec 6. [https://www.tandfonline.com/doi/full/10.3109/10428194.2010.534518 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21133713 PubMed]

==Cladribine monotherapy {{#subobject:f729d6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:986eae|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465670/ Inwards et al. 2008 (NCCTG 95-80-53)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 5 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 5 

'''28-day cycle for up to 6 cycles'''

===References===
# Inwards DJ, Fishkin PA, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Veeder MH, Witzig TE. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008 Jul 1;113(1):108-16. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23537/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465670/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18470909 PubMed]

==Cladribine & Rituximab {{#subobject:9dabc7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:ab63a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465670/ Inwards et al. 2008 (NCCTG N0189)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 5 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 5 
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 6
''OR''
*[[Filgrastim (Neupogen)]] (dose not specified) SC once per day on days 6 to 15

'''28-day cycle for up to 6 cycles'''

===References===
# Inwards DJ, Fishkin PA, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Veeder MH, Witzig TE. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008 Jul 1;113(1):108-16. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23537/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465670/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18470909 PubMed]

==Lenalidomide & Rituximab {{#subobject:517896|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
LR: '''<u>L</u>'''enalidomide & '''<u>R</u>'''ituximab
===Regimen {{#subobject:c021ff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710541/ Ruan et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] as follows:
**Cycle 1: 20 mg PO once per day on days 1 to 21 
**Cycle 2 onwards (if no dose-limiting adverse events in cycle 1): 25 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week on weeks 1 to 4, 13, 21, 29, 37, 45 (total of 9 doses)

====Supportive medications====
*Thromboprophylaxis with [[Aspirin]] or [[:Category:Low molecular weight heparins|low molecular weight heparin]] unless on treatment for known thrombosis

'''28-day cycle for 12 cycles'''
====Subsequent treatment====
*[[#Lenalidomide_.26_Rituximab_2|Maintenance lenalidomide & rituximab]]

===References===
<!-- # '''Abstract:''' Jia Ruan, Peter Martin, Bijal D. Shah, Stephen J. Schuster, Sonali M. Smith, Richard R. Furman, Paul Christos, Amelyn Rodriguez, Paige Wolstencroft, Jakub Svoboda, Alison Bender, Jessica Lewis, Morton Coleman, John P. Leonard. Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab. Blood Nov 2013,122(21)247 [http://www.bloodjournal.org/content/122/21/247 link to abstract]
## '''Update Abstract:''' Jia Ruan, MD, PhD, Peter Martin, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Sonali M. Smith, MD, Richard R Furman, MD, Paul Christos, DrPH, Amelyn Rodriguez, RN, Louisa Drake, Jakub Svoboda, MD, Jessica Lewis, PA-C, Orel Katz, PA-C, Morton Coleman, MD and John P. Leonard, MD. Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report. ASH Annual Meeting 2014 Abstract 625 [https://ash.confex.com/ash/2014/webprogram/Paper73280.html link to abstract] -->
# Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard JP. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015 Nov 5;373(19):1835-44. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505237 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710541/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26535512 PubMed]
## '''Update:''' Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Nov 8;132(19):2016-2025. Epub 2018 Sep 4. [http://www.bloodjournal.org/content/132/19/2016.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30181173 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/27/8/1209.long Martin et al. 2009]
|style="background-color:#ffffbe"|Retrospective
|-
|}

''Also known as "watchful waiting".''

===References===
# '''Retrospective:''' Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009 Mar 10;27(8):1209-13. [http://jco.ascopubs.org/content/27/8/1209.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19188674 PubMed]
# '''Retrospective:''' Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016 Aug 1;122(15):2356-63. Epub 2016 May 6. [https://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30068/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27153197 PubMed]

==R-BAC {{#subobject:3d5221|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-BAC: '''<u>R</u>'''ituximab, '''<u>B</u>'''endamustine, '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)
===Variant #1, 375/70/500 ("RBAC500") {{#subobject:737eac|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30185-5/fulltext Visco et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 2 & 3
*[[Cytarabine (Cytosar)]] 500 mg/m<sup>2</sup> IV once per day on days 2 to 4

'''28-day cycle for up to 6 cycles'''

===Variant #2, 375/70/800 {{#subobject:1f05e1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/31/11/1442.full Visco et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: up to 6 cycles were given for newly diagnosed patients under the age of 80, who tolerated treatment, or had regression of disease between cycles 2 and 4.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1 
**Cycle 2 onwards: 375 mg/m<sup>2</sup> IV once on day 2
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 2 & 3
*[[Cytarabine (Cytosar)]] 800 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 to 4, '''starting 2 hours after bendamustine on days 2 & 3'''

'''28-day cycle for 4 to 6 cycles (see note)'''

===References===
# Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D'Amore ES, Rodeghiero F. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013 Apr 10;31(11):1442-9. Epub 2013 Feb 11. [http://jco.ascopubs.org/content/31/11/1442.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23401442 PubMed]
# Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Di Rocco A, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017 Jan;4(1):e15-e23. Epub 2016 Dec 2. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30185-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27927586 PubMed]

==maxi-R-CHOP/R-HiDAC {{#subobject:360f9d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
maxi-R-CHOP/R-HiDAC: '''<u>maxi</u>'''mum-strength '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone alternating with '''<u>R</u>'''ituximab, '''<u>Hi</u>'''gh-'''<u>D</u>'''ose '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)

===Regimen {{#subobject:b65317|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ Geisler et al. 2008 (Nordic MCL2)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: This is also known as the "Nordic regimen". Protocol originally started rituximab during cycle 4, but the protocol was amended to start it on cycle 2.''
====Chemotherapy, maxi-R-CHOP portion====
*[[Rituximab (Rituxan)]] as follows:
**Cycles 3 & 5: 375 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycles, alternating with R-HiDAC''' 

====Chemotherapy, R-HiDAC portion====
*[[Rituximab (Rituxan)]] as follows:
**Cycles 2 & 4: 375 mg/m<sup>2</sup> IV once on day 1 
**Cycle 6: 375 mg/m<sup>2</sup> IV once per day on days 1 & 9
*[[Cytarabine (Cytosar)]] as follows:
**Patients less than or equal to 60 years old: 3000 mg/m<sup>2</sup> IV over 3 hours every 12 hours on days 1 & 2 (4 total doses)
**Patients greater than 60 years old: 2000 mg/m<sup>2</sup> IV over 3 hours every 12 hours on days 1 & 2 (4 total doses)

====Supportive medications====
*[[Filgrastim (Neupogen)]] given during cycle 6 as part of stem cell mobilization, with at least 2 million CD34+ cells/kg harvested

'''21-day cycles, alternating with maxi-R-CHOP'''
====Subsequent treatment====
*After 6 cycles (3 cycles of maxi-R-CHOP and 3 cycles of R-HiDAC), treatment is followed in 1 to 2 weeks with [[#BEAC.2C_then_auto_HSCT|BEAC with autologous HSCT]] or [[#BEAM.2C_then_auto_HSCT|BEAM with autologous HSCT]]. If transplant was delayed, an additional 1 to 2 cycles of chemotherapy with maxi-R-CHOP or R-HiDAC could be given.

===References===
# '''Nordic MCL2:''' Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. Epub 2008 Jul 14. [http://www.bloodjournal.org/content/112/7/2687.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18625886 PubMed]
## '''Update:''' Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012 Aug;158(3):355-62. Epub 2012 May 29. Erratum in: Br J Haematol. 2012 Sep;158(6):815-6. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09174.x/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22640180 PubMed]
## '''Update:''' Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016 Nov;175(3):410-418. Epub 2016 Jul 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14241/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27378674 PubMed]

==R-DHAC {{#subobject:ed2a61|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-DHAC: '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>C</u>'''arboplatin
===Regimen {{#subobject:c89679|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#CVP|Pre-phase CVP]] x 1 (optional)
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours on day 2 (total of 2 doses)
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*CR: [[#R-BEAM.2C_then_auto_HSCT|R-BEAM with autologous HSCT]]
*PR: [[#R-CHOP-14]] x 4

===References===
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1701769/suppl_file/nejmoa1701769_appendix.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

==R-DHAOx {{#subobject:16a22d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-DHAOx: '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>Ox</u>'''aliplatin
===Regimen {{#subobject:3aa7db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#CVP|Pre-phase CVP]] x 1 (optional)
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours on day 2 (total of 2 doses)
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*CR: [[#R-BEAM.2C_then_auto_HSCT|R-BEAM with autologous HSCT]]
*PR: [[#R-CHOP-14]] x 4

===References===
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1701769/suppl_file/nejmoa1701769_appendix.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

==R-DHAP {{#subobject:7bb19f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-DHAP: '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)
===Variant #1, 3 cycles {{#subobject:b417da|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/121/1/48.full Delarue et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. The authors did not clearly specify the total dose/schedule of cytarabine; below is the dosing used in the [[Diffuse_large_B-cell_lymphoma#R-DHAP|NCIC-CTG LY.12 trial]]''
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 2 to 3 cycles
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV once every 12 hours on day 2 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

====CNS prophylaxis====
''Intrathecal prophylaxis with the following was given per physician discretion; no timeframe or total number of doses is described:''
*[[Methotrexate (MTX)]] 15 mg IT
*[[Cytarabine (Cytosar)]] 40 mg IT
*Corticosteroids

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#TAM6.2C_then_auto_HSCT|TAM6 with auto HSCT]]

===Variant #2, 4 cycles {{#subobject:10fd0a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#CVP|Pre-phase CVP]] x 1 (optional)
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours on day 2 (total of 2 doses)
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*CR: [[#R-BEAM.2C_then_auto_HSCT|R-BEAM with autologous HSCT]]
*PR: [[#R-CHOP-14|R-CHOP-14]] x 4

===References===
# '''Case series:''' de Guibert S, Jaccard A, Bernard M, Turlure P, Bordessoule D, Lamy T. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica. 2006 Mar;91(3):425-6. [http://www.haematologica.org/content/91/3/425 link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16531272 PubMed]
# Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O; for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013 Jan 3;121(1):48-53. Epub 2012 Jun 20. [http://www.bloodjournal.org/content/121/1/48.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22718839 PubMed]
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1701769/suppl_file/nejmoa1701769_appendix.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

==R-HiDAC {{#subobject:3a58eb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-HiDAC: '''<u>R</u>'''ituximab & '''<u>Hi</u>'''gh '''<u>D</u>'''ose '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)
===Variant #1, Ara-C 2000 mg/m<sup>2</sup> {{#subobject:395100|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07498.x/full Van 't Veer et al. 2008 (HOVON 45)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 3
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 11
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours on days 1 to 4 (8 total doses)

'''One course'''
====Subsequent treatment====
*Stem cells were collected after this cycle with G-CSF given to "enhance" collection. Patients then proceeded to [[#BEAM.2C_then_auto_HSCT|BEAM with autologous HSCT]]

===Variant #2, Ara-C 3000 mg/m<sup>2</sup> {{#subobject:e780a4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13929/full Armand et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. See paper for advice on cytarabine dose reduction.''
====Preceding treatment====
*[[#BR|RB]] x 3
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2 (4 doses)

'''3 cycles (duration not specified)'''
====Subsequent treatment====
*High-dose therapy with autologous HSCT

===References===
# Van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009 Feb;144(4):524-30. Epub 2008 Nov 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07498.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19036081 PubMed]
# Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED. A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr;173(1):89-95. Epub 2016 Jan 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13929/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26729345 PubMed]

==R-M-CHOP {{#subobject:358013|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-M-CHOP: '''<u>R</u>'''ituximab, '''<u>MTX</u>''' (Methotrexate), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone
===Regimen {{#subobject:e580e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ Damon et al. 2009 (CALGB 59909)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is the induction portion ("Treatments 1 & 2") of CALGB 59909. Median days between treatment 1 & 2 was 23 days, with a range of 16 to 41 days observed.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 
**Withheld if circulating mantle cells are greater than 10,000 cells/uL
*[[Methotrexate (MTX)]] 300 mg/m<sup>2</sup> IV over 4 hours once on day 2
*[[Cyclophosphamide (Cytoxan)]] 2000 mg/m<sup>2</sup> IV over 2 hours once on day 3
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 3
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg for patients greater than 40 years old) IV once on day 3
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 3 to 7

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 50 mg/m<sup>2</sup> IV every 6 hours x 3 doses, starting 24 hours after completion of [[Methotrexate (MTX)]], then 10 mg/m<sup>2</sup> IV or PO every 6 hours until serum methotrexate level less than 50 nmol/L
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 4, to continue until ANC greater than 10,000/uL once or greater than 5000/uL twice 
*[[Levofloxacin (Levaquin)]] 500 mg PO once per day, starting on day 6, to continue until ANC is greater than or equal to 1500/uL
*[[Fluconazole (Diflucan)]] 200 mg PO once per day, starting on day 6, to continue until ANC is greater than or equal to 1500/uL

'''2 cycles, with interval between cycle 1 & 2 based on count recovery'''
====Subsequent treatment====
*Patients with less than or equal to 15% involvement by disease in bone marrow biopsy after cycle 2: [[Stem_cell_mobilization#EAR_.26_G-CSF|EAR with stem cell mobilization]], 4 weeks after treatment 2, if ANC greater than or equal to 1000/uL, platelets greater than or equal to 100 x 10<sup>9</sup>/L, Cr less than 2 mg/dL, total bilirubin less than 2x upper limit of normal, and AST less than 3x upper limit of normal. 
*Patients with bone marrow biopsy after treatment 2 has greater than 15% involvement by disease, repeat treatment 2 (identified as "treatment 2.5")
*Patients with greater than 15% bone marrow involvement by disease after treatment 2.5 were removed from protocol

====CNS therapy====
If cerebrospinal fluid (CSF) contained disease with CSF WBC count greater than or equal to 5 cells/uL:
*[[Methotrexate (MTX)]] 12 mg IT x 10 total doses during treatments 1 to 3; not given concurrently with intrathecal methotrexate or cytarabine

If CSF contained greater than 5 cells/uL: 
*In addition to intrathecal chemotherapy above, patient also received 2 Gy x 12 fractions (total dose 24 Gy) [[External_beam_radiotherapy|cranial radiation]] 

===References===
# Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [http://jco.ascopubs.org/content/27/36/6101.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19917845 PubMed]

==R-MACLO/R-IVAM {{#subobject:51391f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-MACLO/R-IVAM: '''<u>R</u>'''ituximab, '''<u>MTX</u>''' (Methotrexate), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>O</u>'''ncovin (Vincristine) alternating with '''<u>R</u>'''ituximab, '''<u>V</u>'''P-16 (Etoposide), '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine), '''<u>M</u>'''esna

===Variant #1 {{#subobject:fdf7f7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428190903518345 Lossos et al. 2010 (UM-MCL1)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy, R-MACLO portion (Cycles 1 & 3)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 1, then 200 mg/m<sup>2</sup> IV once per day on days 2 to 5
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1 & 8
*[[Methotrexate (MTX)]] 1200 mg/m<sup>2</sup> IV over 60 minutes once on day 10, then 5520 mg/m<sup>2</sup> IV continuous infusion over 23 hours (total dose per cycle: 6720 mg/m<sup>2</sup>)

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 180 mg/m<sup>2</sup> IV once 12 hours after [[Methotrexate (MTX)]] is complete, then 12 mg/m<sup>2</sup> IV Q6H for at least 10 doses or until serum methotrexate level is less than 50 nmol/L
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] given starting on day 13, continued until ANC greater than 1500/uL for two consecutive days

'''Next cycle to start after count recovery'''

====Chemotherapy, R-IVAM portion (Cycles 2 & 4)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2 (4 doses total)
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 5

====Supportive medications====
*[[Mesna (Mesnex)]] 360 mg/m<sup>2</sup> IV starting "prior to [[Ifosfamide (Ifex)]]" and given Q3H through day 5 (total of 40 doses)
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] given starting on day 7, continued until ANC greater than 1500/uL for two consecutive days

'''Next cycle to start after count recovery + 2 weeks'''

'''Total of 4 cycles'''
====Subsequent treatment====
*Patients achieving a CR: thalidomide maintenance

===Variant #2 {{#subobject:ee6728|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428190903518345 Lossos et al. 2010 (UM-MCL2)]
|style="background-color:#91cf61"|Phase II
|-
|}
''The only difference between this regimen and regimen #1 above is the dose of the MTX and the maintenance portion. It is unclear from the text whether the total dose of MTX is reduced to 3000 mg/m<sup>2</sup> or if the 23 hour infusional portion is reduced to 3000 mg/m<sup>2</sup>.''

====Chemotherapy, R-MACLO portion (Cycles 1 & 3)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 1, then 200 mg/m<sup>2</sup> IV once per day on days 2 to 5
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1 & 8
*[[Methotrexate (MTX)]] 1200 mg/m<sup>2</sup> IV over 60 minutes once on day 10, then 3000 mg/m<sup>2</sup> IV continuous infusion over 23 hours (total dose per cycle: 4200 mg/m<sup>2</sup>)

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 180 mg/m<sup>2</sup> IV once 12 hours after [[Methotrexate (MTX)]] is complete, then 12 mg/m<sup>2</sup> IV Q6H for at least 10 doses or until serum methotrexate level is less than 50 nmol/L
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] given starting on day 13, continued until ANC greater than 1500/uL for two consecutive days

'''Next cycle to start after count recovery'''

====Chemotherapy, R-IVAM portion (Cycles 2 & 4)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2 (4 doses total)
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 5

====Supportive medications====
*[[Mesna (Mesnex)]] 360 mg/m<sup>2</sup> IV starting "prior to [[Ifosfamide (Ifex)]]" and given Q3H through day 5 (total of 40 doses)
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] given starting on day 7, continued until ANC greater than 1500/uL for two consecutive days

'''Next cycle to start after count recovery + 2 weeks'''

'''Total of 4 cycles'''
====Subsequent treatment====
*Patients achieving a CR: [[#Rituximab_monotherapy|Rituximab maintenance]]

===References===
# '''UM-MCL1/UM-MCL2:''' Lossos IS, Hosein PJ, Morgensztern D, Coleman F, Escalón MP, Byrne GE Jr, Rosenblatt JD, Walker GR. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2010 Mar;51(3):406-14. [http://www.tandfonline.com/doi/full/10.3109/10428190903518345 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20038221 PubMed]
## '''Update:''' Hosein PJ, Sandoval-Sus JD, Goodman D, Arteaga AG, Reis I, Hoffman J, Stefanovic A, Rosenblatt JD, Lossos IS. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Am J Hematol. 2015 Jun;90(6):E111-6. Epub 2015 Apr 2. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23996/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439262/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25737247 PubMed]

==RiPAD+C {{#subobject:438664|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RiPAD+C: '''<u>Ri</u>'''tuximab, '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone, '''<u>C</u>'''hlorambucil

===Regimen {{#subobject:c36f20|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/23/6/1555.long Houot et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1 & 8
**Cycle 2 onwards: 375 mg/m<sup>2</sup> IV once on day 1
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> (route not specified) once per day on days 1, 4, 8, 11
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m<sup>2</sup>)
*[[Dexamethasone (Decadron)]] 20 mg (route not specified) twice per day on days 1 to 4
*[[Chlorambucil (Leukeran)]] 12 mg PO once per day on days 20 to 29

'''35-day cycle for up to 6 cycles'''

===References===
# Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C, Bouabdallah K, Alexis Vigier M, Moles MP, Tournilhac O, Arakelyan N, Rodon P, El Yamani A, Sutton L, Fornecker L, Assouline D, Harousseau JL, Maisonneuve H, Caulet-Maugendre S, Gressin R; French GOELAMS group. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol. 2012 Jun;23(6):1555-61. Epub 2011 Oct 19. [http://annonc.oxfordjournals.org/content/23/6/1555.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22012966 PubMed]

==R-VAD+C {{#subobject:456435|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-VAD+C: '''<u>R</u>'''ituximab, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone, '''<u>C</u>'''hlorambucil
===Regimen {{#subobject:332e75|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ Gressin et al. 2010 (GOELAMS LM2001)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg/m<sup>2</sup>)
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m<sup>2</sup>)
*[[Dexamethasone (Decadron)]] 20 mg IV or PO twice per day on days 1 to 4
*[[Chlorambucil (Leukeran)]] 12 mg PO once per day on days 20 to 29

'''35-day cycle for 4 to 8 cycles'''
====Subsequent treatment====
*Transplant-eligible patients with more than partial response after 4 cycles: [[#Melphalan_.26_TBI.2C_then_auto_HSCT|High-dose melphalan & TBI, then autologous HSCT]] 4 weeks after the 6th cycle

===References===
# '''GOELAMS LM2001:''' Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. [http://www.haematologica.org/content/95/8/1350.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20220059 PubMed]

==VAD+C {{#subobject:69bd40|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VAD+C: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone, '''<u>C</u>'''hlorambucil
===Regimen {{#subobject:cfee50|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ Gressin et al. 2010 (GOELAMS LM1996)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg/m<sup>2</sup>)
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m<sup>2</sup>)
*[[Dexamethasone (Decadron)]] 20 mg IV or PO twice per day on days 1 to 4
*[[Chlorambucil (Leukeran)]] 12 mg PO once per day on days 20 to 29

'''35-day cycle for 4 to 8 cycles'''
====Subsequent treatment====
*Transplant-eligible patients with more than partial response after 4 cycles: [[#Melphalan_.26_TBI.2C_then_auto_HSCT|High-dose melphalan & TBI, then autologous HSCT]] 4 weeks after the 6th cycle

===References===
# '''GOELAMS LM1996:''' Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. [http://www.haematologica.org/content/95/8/1350.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20220059 PubMed]

==VcR-CVAD {{#subobject:2494f3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VcR-CVAD: '''<u>V</u>'''el'''<u>c</u>'''ade (Bortezomib), '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone

===Regimen {{#subobject:bb2a6e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188692/ Chang et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954048/ Chang et al. 2014 (ECOG E1405)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV over 3 hours every 12 hours x 6 doses on days 1 to 3 (total dose per cycle: 1800 mg/m<sup>2</sup>)
*[[Vincristine (Oncovin)]] 1 mg IV once on day 3
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours, started on day 1 (total dose per cycle: 100 mg/m<sup>2</sup>)
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

====Supportive medications====
*[[Mesna (Mesnex)]] dose not specified Chang et al. 2011; not mentioned in Chang et al. 2014
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day or [[Pegfilgrastim (Neulasta)]] on day 5 or 6 of each cycle

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*ECOG E1405, at least PR: [[#Rituximab_monotherapy|Maintenance rituximab]] or high-dose therapy with autologous HSCT (regimen not specified), patient choice

===References===
# Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7. Epub 2011 Aug 16. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08820.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188692/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21848883 PubMed]
# '''ECOG E1405:''' Chang JE, Li H, Smith MR, Gascoyne RD, Paietta EM, Yang DT, Advani RH, Horning SJ, Kahl BS. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014 Mar 13;123(11):1665-73. Epub 2014 Jan 23. [http://www.bloodjournal.org/content/123/11/1665.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954048/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24458437 PubMed]

==VR-CHOP {{#subobject:f5739b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VR-CHOP: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Regimen {{#subobject:e54ea1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/29/6/690.long Ruan et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710555/ Till et al. 2015 (SWOG S0601)]
|style="background-color:#91cf61"|Phase II
|-
|}

''Doses here are the phase II dose of bortezomib and the R-CHOP protocol as specified in the phase I report by Furman et al. 2010''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1 & 4, '''given first on day 1'''
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*"Standard" [[Acetaminophen (Tylenol)]] and [[Diphenhydramine (Benadryl)]] prior to [[Rituximab (Rituxan)]]

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*SWOG S0601: [[#Bortezomib_monotherapy|Bortezomib maintenance]]

===References===
# Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Feb 20;29(6):690-7. Epub 2010 Dec 28. [http://jco.ascopubs.org/content/29/6/690.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21189393 PubMed]
# '''SWOG S0601:''' Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016 Jan;172(2):208-18. Epub 2015 Oct 22. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13818/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710555/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26492567 PubMed]

=Consolidation after first-line therapy=
==BEAC, then auto HSCT {{#subobject:0341c3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAC: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:760828|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ Geisler et al. 2008 (MCL1/MCL2)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#maxi-R-CHOP.2FR-HiDAC|maxi-R-CHOP/R-HiDAC]] x 6 to 8
{{#lst:Autologous HSCT conditioning regimens|1a6845}}
'''Stem cells reinfused after chemotherapy, unclear exactly which day'''

===References===
# '''Nordic MCL2:''' Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. Epub 2008 Jul 14. [http://www.bloodjournal.org/content/112/7/2687.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18625886 PubMed]
## '''Update:''' Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012 Aug;158(3):355-62. Epub 2012 May 29. Erratum in: Br J Haematol. 2012 Sep;158(6):815-6. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09174.x/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22640180 PubMed]
## '''Update:''' Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016 Nov;175(3):410-418. Epub 2016 Jul 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14241/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27378674 PubMed]

==BEAM, then auto HSCT {{#subobject:ed61ad|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAM: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Variant #1 {{#subobject:9fff3a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ Geisler et al. 2008 (MCL1/MCL2)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#maxi-R-CHOP.2FR-HiDAC|maxi-R-CHOP/R-HiDAC]] x 6 to 8
{{#lst:Autologous HSCT|2821aa}}
'''Stem cells re-infused after chemotherapy, unclear exactly which day'''

===Variant #2 {{#subobject:970002|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07498.x/full Van 't Veer et al. 2008 (HOVON 45)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 3, then [[#R-HiDAC|R-HiDAC]] x 1
{{#lst:Autologous HSCT|f28f87}}
'''Stem cells re-infused on day 0'''

===References===
# '''Nordic MCL2:''' Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. Epub 2008 Jul 14. [http://www.bloodjournal.org/content/112/7/2687.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18625886 PubMed]
## '''Update:''' Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012 Aug;158(3):355-62. Epub 2012 May 29. Erratum in: Br J Haematol. 2012 Sep;158(6):815-6. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09174.x/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22640180 PubMed]
## '''Update:''' Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016 Nov;175(3):410-418. Epub 2016 Jul 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14241/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27378674 PubMed]
# Van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009 Feb;144(4):524-30. Epub 2008 Nov 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07498.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19036081 PubMed]
# '''SWOG S1106:''' Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017 Mar;176(5):759-769. Epub 2016 Dec 19. [https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14480 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318240/ link to PMC article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27992063 PubMed]

==CBV, then auto HSCT {{#subobject:292784|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CBV: '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''iCNU (Carmustine), '''<u>V</u>'''P-16 (Etoposide)
===Regimen {{#subobject:55f221|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ Damon et al. 2009 (CALGB 59909)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is the transplant portion ("Treatment 4") of CALGB 59909.''
====Preceding treatment====
*[[Stem_cell_mobilization#EAR_.26_G-CSF|EAR & stem cell mobilization]]
{{#lst:Autologous HSCT conditioning regimens|35a696}}
====Treatment 5, Rituximab====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week x 2 doses, during the sixth and seventh weeks after ASCT

====Additional considerations====
If any patient appeared to be experiencing carmustine-induced pneumonitis:
*[[Prednisone (Sterapred)]] 0.5 mg/kg PO twice per day x 2 weeks, then tapered over 4 weeks

===References===
# '''CALGB 59909:''' Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [http://jco.ascopubs.org/content/27/36/6101.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19917845 PubMed]
# '''SWOG S1106:''' Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017 Mar;176(5):759-769. Epub 2016 Dec 19. [https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14480 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318240/ link to PMC article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27992063 PubMed]

==Cyclophosphamide & TBI, then auto HSCT {{#subobject:0a4915|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CY/TBI: '''<u>CY</u>'''clophosphamide & '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
===Regimen {{#subobject:a2b2d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/105/7/2677.long Dreyling et al. 2004]
| style="background-color:#1a9851" |Phase III (E)
|[[#Interferon_alfa_monotherapy|Interferon alfa]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Preceding treatment====
*CHOP-like chemotherapy x 4 to 6, then [[Stem_cell_mobilization#DexaBEAM_.26_G-CSF|Dexa-BEAM & G-CSF mobilization]]
{{#lst:Autologous HSCT conditioning regimens|a2b2d3}}
'''Stem cells re-infused on day 0'''
===References===
# Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [http://www.bloodjournal.org/content/105/7/2677.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15591112 PubMed]

==Ibritumomab tiuxetan monotherapy {{#subobject:165cb4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f0c3d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732008/ Smith et al. 2012 (ECOG E1499)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 4
====Chemotherapy====
*[[Rituximab (Rituxan)]] 250 mg/m<sup>2</sup> IV once on day 1, then another single dose on day 8, '''given first'''
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin) ]] 0.4 mCi/kg (maximum dose of 32 mCi) IV once on day 8, '''given second'''
**Dose-reduced to 0.3 mCi/kg if platelet count between 100 and 149 x 10<sup>9</sup>/L

'''One course'''

===References===
<!-- Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006; the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2007; and the 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011. -->
# Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012 Sep 1;30(25):3119-26. Epub 2012 Jul 30. [http://jco.ascopubs.org/content/30/25/3119.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732008/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22851557 PubMed]
## '''Update:''' Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, Advani RH, Forero-Torres A, Horning SJ, Kahl BS. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia. 2017 Feb;31(2):517-519. Epub 2016 Oct 26. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288271/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27780968 PubMed]

==Melphalan & TBI, then auto HSCT {{#subobject:94f995|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TBI: '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
===Regimen {{#subobject:ad4db8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/95/8/1350.full Gressin et al. 2010 (GOELAMS LM1996)]
| style="background-color:#91cf61" |Phase II
|-
|[http://www.haematologica.org/content/95/8/1350.full Gressin et al. 2010 (GOELAMS LM2001)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*GOELAMS LM1996: [[#VAD.2BC|VAD+C]] x 6
*GOELAMS LM2001: [[#R-VAD.2BC|R-VAD+C]] x 6
{{#lst:Autologous HSCT conditioning regimens|ad4db8}}
'''Stem cells reinfused after chemoradiotherapy, unclear exactly which day'''

===References===
# '''GOELAMS LM1996/LM2001:''' Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. [http://www.haematologica.org/content/95/8/1350.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ link to PMC article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20220059 PubMed]

==R-BEAM, then auto HSCT {{#subobject:87ade5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-BEAM: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:c0248f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*CR: [[#R-DHAC|R-DHAC]] x 4 or [[#R-DHAOx|R-DHAOx]] x 4 or [[#R-DHAP|R-DHAP]] x 4
*PR: [[#R-DHAC|R-DHAC]] x 4 or [[#R-DHAOx|R-DHAOx]] x 4 or [[#R-DHAP|R-DHAP]] x 4, then [[#R-CHOP-14|R-CHOP-14]] x 4
{{#lst:Autologous HSCT conditioning regimens|db487f}}
'''Stem cells re-infused on day 0'''
====Subsequent treatment====
*[[#Observation_2|Observation]] versus [[#Rituximab_monotherapy|Rituximab maintenance]]
===References===
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

==TAM6, then auto HSCT {{#subobject:c810fd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TAM: '''<u>T</u>'''otal-body irradiation, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:4aee7c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/121/1/48.full Delarue et al. 2012]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#R-DHAP|R-DHAP]] x 3
{{#lst:Autologous HSCT conditioning regimens|4aee7c}}
===References===
# Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O; for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013 Jan 3;121(1):48-53. Epub 2012 Jun 20. [http://www.bloodjournal.org/content/121/1/48.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22718839 PubMed]

=Maintenance after first-line therapy=

==Bortezomib monotherapy {{#subobject:018719|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:1099af|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710555/ Till et al. 2015 (SWOG S0601)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#VR-CHOP|VR-CHOP]] x 6
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

'''3-month cycle for 2 years''' 

===References===
# '''SWOG S0601:''' Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016 Jan;172(2):208-18. Epub 2015 Oct 22. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13818/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710555/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26492567 PubMed]

==Interferon alfa monotherapy {{#subobject:f7b23b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e5b536|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/105/7/2677.long Dreyling et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cyclophosphamide_.26_TBI.2C_then_auto_HSCT|Cy/TBI, then auto HSCT]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 Kluin-Nelemans et al. 2012 (MCLelderly)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#1a9850"|Inferior combined OS (*)
|-
|}
''Note: in MCLelderly, inferiority was only demonstrated in the group of patients who got R-CHOP first; overall, there was no statistically significant survival difference between the two maintenance groups.''
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 8 versus [[#FCR|R-FC]] x 6
====Immunotherapy====
*[[:Category:Interferons|Interferon alfa]]

'''Continued indefinitely'''

===References===
# Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [http://www.bloodjournal.org/content/105/7/2677.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15591112 PubMed]
# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22873532 PubMed]

==Lenalidomide & Rituximab {{#subobject:6bd100|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:d64401|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710541/ Ruan et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Lenalidomide_.26_Rituximab|Lenalidomide & Rituximab induction]]
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21 
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 every other cycle (every 8 weeks)

'''28-day cycles'''

===References===
<!-- # '''Abstract:''' Jia Ruan, Peter Martin, Bijal D. Shah, Stephen J. Schuster, Sonali M. Smith, Richard R. Furman, Paul Christos, Amelyn Rodriguez, Paige Wolstencroft, Jakub Svoboda, Alison Bender, Jessica Lewis, Morton Coleman, John P. Leonard. Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab. Blood Nov 2013,122(21)247 [http://www.bloodjournal.org/content/122/21/247 link to abstract]
## '''Update Abstract:''' Jia Ruan, MD, PhD, Peter Martin, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Sonali M. Smith, MD, Richard R Furman, MD, Paul Christos, DrPH, Amelyn Rodriguez, RN, Louisa Drake, Jakub Svoboda, MD, Jessica Lewis, PA-C, Orel Katz, PA-C, Morton Coleman, MD and John P. Leonard, MD. Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report. ASH Annual Meeting 2014 Abstract 625 [https://ash.confex.com/ash/2014/webprogram/Paper73280.html link to abstract] -->
# Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard JP. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med. 2015 Nov 5;373(19):1835-44. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505237 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710541/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26535512 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''This arm received no further treatment after transplant.''
====Preceding treatment====
*[[#BEAM.2C_then_auto_HSCT|R-BEAM with autologous HSCT]]

===References===
# Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trümper L, Nahler M, Reuss-Borst M, Tirier C, Neubauer A, Freund M, Kreuser ED, Dietzfelbinger H, Bodenstein H, Engert A, Stauder R, Eimermacher H, Landys K, Hiddemann W; German Low-Grade Lymphoma Study Group. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. Leukemia. 1996 May;10(5):836-43. [https://www.ncbi.nlm.nih.gov/pubmed/8656680 PubMed]
## '''Update:''' Hiddemann W, Unterhalt M, Herrmann R, Wöltjen HH, Kreuser ED, Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath RD, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Parwaresch R. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998 May;16(5):1922-30. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.5.1922 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9586911 PubMed]
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

==Rituximab monotherapy {{#subobject:712b01|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 6 doses {{#subobject:7b2206|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2010.534518 Sachanas et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Chlorambucil_.26_Rituximab|Chlorambucil & Rituximab]] x 12
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 2 months

'''12-month course'''

===Variant #2, 12 doses {{#subobject:c9438a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2012.672736 Räty et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*Induction chemotherapy x 10, with CR/PR
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 2 months

'''2-year course'''

===Variant #3, 16 doses {{#subobject:ab3766|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954048/ Chang et al. 2014 (ECOG E1405)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#VcR-CVAD|VcR-CVAD]] x 6
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week for four weeks

'''Course repeats every 6 months for 2 years'''

===Variant #4, 18 doses {{#subobject:572f85|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Preceding treatment====
*[[#BEAM.2C_then_auto_HSCT|R-BEAM with autologous HSCT]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 2 months

'''3-year course'''

===Variant #5, 24 doses {{#subobject:4ad905|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428190903518345 Lossos et al. 2010 (UM-MCL2)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-MACLO.2FR-IVAM|R-MACLO/R-IVAM]] x 4
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week for four weeks

'''Course repeats every 6 months for 3 years'''

===Variant #6, indefinite {{#subobject:f46cd3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 Kluin-Nelemans et al. 2012 (MCLelderly)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Interferon_alfa_monotherapy|Interferon alfa]]
|style="background-color:#1a9850"|Superior combined OS (*)
|-
|}
''Note: superiority was only demonstrated in the group of patients who got R-CHOP first; overall, there was no statistically significant survival difference between the two maintenance groups.''
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 8 versus [[#FCR|R-FC]] x 6
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 2 months

'''Continued indefinitely'''

===References===
# '''UM-MCL1/UM-MCL2:''' Lossos IS, Hosein PJ, Morgensztern D, Coleman F, Escalón MP, Byrne GE Jr, Rosenblatt JD, Walker GR. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2010 Mar;51(3):406-14. [http://www.tandfonline.com/doi/full/10.3109/10428190903518345 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20038221 PubMed]
## '''Update:''' Hosein PJ, Sandoval-Sus JD, Goodman D, Arteaga AG, Reis I, Hoffman J, Stefanovic A, Rosenblatt JD, Lossos IS. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Am J Hematol. 2015 Jun;90(6):E111-6. Epub 2015 Apr 2. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23996/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439262/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25737247 PubMed]
# Sachanas S, Pangalis GA, Vassilakopoulos TP, Korkolopoulou P, Kontopidou FN, Athanasoulia M, Yiakoumis X, Kalpadakis C, Georgiou G, Masouridis S, Moschogiannis M, Tsirkinidis P, Pappis V, Kokoris SI, Siakantaris MP, Panayiotidis P, Angelopoulou MK. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma. 2011 Mar;52(3):387-93. Epub 2010 Dec 6. [https://www.tandfonline.com/doi/full/10.3109/10428194.2010.534518 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21133713 PubMed]
# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1200920 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22873532 PubMed]
# Räty R, Honkanen T, Jantunen E, Jyrkkiö S, Karjalainen-Lindsberg ML, Kuittinen O, Lehto M, Mikkola M, Poikonen E, Rauhala A, Rimpiläinen J, Räsänen A, Siitonen S, Suominen M, Vapaatalo M, Elonen E. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group. Leuk Lymphoma. 2012 Oct;53(10):1920-8. Epub 2012 Apr 23. [https://www.tandfonline.com/doi/full/10.3109/10428194.2012.672736 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22397313 PubMed]
## '''Update: Abstract:''' Riikka Räty, Tuomo Honkanen, Esa Jantunen, MD, PhD, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Outi Kuittinen, Minna Lehto, Maija Mikkola, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, MD, Sanna Siitonen, Merja Suominen, MD, Mirja Vapaatalo and Erkki Elonen. Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group. Blood 2014 124:1749. [http://www.bloodjournal.org/content/124/21/1749 link to abstract]
# '''ECOG E1405:''' Chang JE, Li H, Smith MR, Gascoyne RD, Paietta EM, Yang DT, Advani RH, Horning SJ, Kahl BS. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014 Mar 13;123(11):1665-73. Epub 2014 Jan 23. [http://www.bloodjournal.org/content/123/11/1665.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954048/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24458437 PubMed]
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
# Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://www.nejm.org/doi/full/10.1056/NEJMoa1701769 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28953447 PubMed]

=Relapsed or refractory, randomized data=

==BCHOP {{#subobject:3dbcd7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BCHOP: '''<u>B</u>'''ortezomib, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone

===Regimen {{#subobject:a32960|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13101/full Furtado et al. 2014]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#CHOP_2|CHOP]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.6 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*[[Acyclovir (Zovirax)]] 400 mg PO twice per day

'''21-day cycle for up to 8 cycles'''

===References===
<!-- Previously presented in part (in poster form) at the 17th Congress of the European Haematology Association, June 2012 and orally at the BSH annual scientific meeting 2013. -->
# Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. Epub 2014 Aug 22. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13101/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25146720 PubMed]

==BR {{#subobject:3a2a8c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab

===Variant #1 {{#subobject:ad6e9d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://link.springer.com/article/10.1007/s00277-015-2478-9/fulltext.html Czuczman et al. 2015]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext Rummel et al. 2015 (StiL NHL 2-2003)]
|style="background-color:#1a9851"|Phase III (E)
|[[#FR|FR]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}

====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2 
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*Analgesics and antipyretics prior to each dose of [[Rituximab (Rituxan)]]

'''28-day cycle for 6 to 8 cycles'''

===Variant #2 {{#subobject:3f43c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/jco.2005.08.100 Rummel et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|-
|[http://jco.ascopubs.org/content/26/27/4473.long Robinson et al. 2008]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|-
|}
''Note: Robinson et al. 2008 said that patients "could receive up to six cycles if disease regression was evident between the second and fourth cycles".''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**One week prior to start of cycle 1: 375 mg/m<sup>2</sup> IV once
**Cycles 1 to 4: 375 mg/m<sup>2</sup> IV once on day 1
**4 weeks after cycle 4: 375 mg/m<sup>2</sup> IV once
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 2 & 3

'''28-day cycle for 4 cycles (Rummel et al. 2005) or up to 6 cycles (Robinson et al. 2008; see note)'''

===References===
<!-- No prepublication disclosed -->
# Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. [http://ascopubs.org/doi/full/10.1200/jco.2005.08.100 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15908650 PubMed]
<!-- Preliminary results were presented at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL. -->
# Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008 Sep 20;26(27):4473-9. Epub 2008 Jul 14. [http://jco.ascopubs.org/content/26/27/4473.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18626004 PubMed]
# Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol. 2015 Dec;94(12):2025-32. Epub 2015 Sep 28. [http://link.springer.com/article/10.1007/s00277-015-2478-9/fulltext.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26411584 PubMed]
<!-- # '''Abstract:''' Mathias J. Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke and Juergen Barth. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2010, Abstract 856 [https://ash.confex.com/ash/2010/webprogram/Paper26917.html link to abstract]
## '''Update:''' '''Abstract:''' Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2014, Abstract 145 [https://ash.confex.com/ash/2014/webprogram/Paper69154.html link to abstract] -->
# '''StiL NHL 2-2003:''' Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26655425 PubMed]

==CHOP {{#subobject:a01b9f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone

===Regimen {{#subobject:ebce4e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13101/full Furtado et al. 2014]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#BCHOP|BCHOP]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for 6 to 8 cycles'''

===References===
<!-- Previously presented in part (in poster form) at the 17th Congress of the European Haematology Association, June 2012 and orally at the BSH annual scientific meeting 2013. -->
# Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. Epub 2014 Aug 22. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13101/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25146720 PubMed]

==FCM {{#subobject:ddc2e3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FCM: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''itoxantrone
===Regimen {{#subobject:32ca30|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|[[#R-FCM|R-FCM]]
|style="background-color:#d73027"|Inferior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV over 4 hours on days 1 to 3
*[[Mitoxantrone (Novantrone)]] 8 mg/m<sup>2</sup> IV over 30 minutes once on day 1

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*PR/CR: [[#Rituximab_monotherapy_2|Rituximab maintenance]] versus [[#Observation_3|no further treatment]]

===References===
# Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. [http://www.bloodjournal.org/content/104/10/3064.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15284112 PubMed] content property of [http://hemonc.org HemOnc.org]
## '''Update:''' Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. [http://www.bloodjournal.org/content/108/13/4003.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16946304 PubMed]

==FR {{#subobject:d61742|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FR: '''<u>F</u>'''ludarabine, '''<u>R</u>'''ituximab

===Regimen {{#subobject:2592a5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext Rummel et al. 2015 (StiL NHL 2-2003)]
|style="background-color:#1a9851"|Phase III (C)
|[[#BR_2|BR]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for up to 6 cycles'''

===References===
<!-- # '''Abstract:''' Mathias J. Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke and Juergen Barth. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2010, Abstract 856 [https://ash.confex.com/ash/2010/webprogram/Paper26917.html link to abstract]
## '''Update:''' '''Abstract:''' Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2014, Abstract 145 [https://ash.confex.com/ash/2014/webprogram/Paper69154.html link to abstract] -->
# Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00447-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26655425 PubMed]

==Ibrutinib monotherapy {{#subobject:1e0d5c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:529650|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513941/ Wang et al. 2013 (PCYC-1104-CA)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00667-4/fulltext Dreyling et al. 2015 (RAY)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Temsirolimus_monotherapy|Temsirolimus]]
|style="background-color:#1a9850"|Superior PFS
|style="background-color:#1a9850"|Improved HRQoL
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 560 mg PO once per day

'''Continued indefinitely'''

===References===
# '''PCYC-1104-CA:''' Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8;369(6):507-16. Epub 2013 Jun 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa1306220 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513941/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23782157 PubMed]
## '''Update: Abstract:''' Michael Wang, MD, Simon Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, PhD, Brad S. Kahl, MD, Wojciech Jurczak, Ranjana Advani, MD, Jorge E. Romaguera, MD, Michael E. Williams, MD, Jacqueline C. Barrientos, M.D., Ewa Chmielowska, MD, John Radford, Stephan Stilgenbauer, MD, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, MD, Peter W Johnson, MD, Stephen E. Spurgeon, MD, Liang Zhang, MD, PhD, Linda Baher, Mei Cheng, PhD, Darrin M. Beaupre, MD and Kristie A. Blum, MD. Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. Blood 2014 124:4453. [http://www.bloodjournal.org/content/124/21/4453 link to abstract]
## '''Update:''' Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45. Epub 2015 Jun 9. [http://www.bloodjournal.org/content/126/6/739 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528064/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26059948 PubMed]
# '''RAY:''' Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016 Feb 20;387(10020):770-8. Epub 2015 Dec 4. Erratum in: Lancet. 2016 Feb 20;387(10020):750.[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00667-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26673811 PubMed]
## '''HRQoL analysis:''' Hess G, Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Caballero D, Joao C, Witzens-Harig M, Bence-Bruckler I, Cho SG, Zhou W, Goldberg JD, Trambitas C, Enny C, Vermeulen J, Traina S, Chiou CF, Diels J, Dreyling M. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leuk Lymphoma. 2017 Dec;58(12):2824-2832. Epub 2017 May 30. [https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1326034 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28556689 PubMed]
## '''Update:''' Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018 Aug;32(8):1799-1803. Epub 2018 Feb 2. [https://www.nature.com/articles/s41375-018-0023-2 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087720/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29572505 PubMed]

==Lenalidomide monotherapy {{#subobject:b5de78|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:2d2b4a|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/30/4952.long Wiernik et al. 2008 (NHL-002)]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07626.x/full Habermann et al. 2009]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://annonc.oxfordjournals.org/content/22/7/1622.long Witzig et al. 2011 (NHL-003)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12008/full Eve et al. 2012]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879693/ Goy et al. 2013 (EMERGE)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00559-8/fulltext Trněný et al. 2016 (SPRINT)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Investigator's choice of:<br> 1. Chlorambucil<br> 2. Cytarabine<br> 3. Fludarabine<br> 4. Gemcitabine<br> 5. Rituximab
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Participants in '''EMERGE''' "were required to have had prior treatment with rituximab, cyclophosphamide and anthracycline (or mitoxantrone), and to have relapsed or progressed (<12 months) after or were refractory to bortezomib." Investigator's choice in the '''SPRINT''' trial was restricted to single-agent therapy with cytarabine, rituximab, gemcitabine, fludarabine, or chlorambucil.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycles'''
====Subsequent treatment====
*Eve et al. 2012: [[#Lenalidomide_monotherapy_2|Lenalidomide maintenance]] after 6 cycles

===References===
<!-- Presented in part as oral presentations at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL, and the 3rd International Conference of Innovative Therapies for Lymphoid Malignancies, September 28, 2006, Palermo, Italy; and as poster presentations at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL, the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the Pan Pacific Lymphoma Conference, June 11-15, 2007, Maui, HI. -->
# '''NHL-002:''' Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20;26(30):4952-7. Epub 2008 Jul 7. [http://jco.ascopubs.org/content/26/30/4952.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18606983 PubMed]
## '''Pooled Update:''' Witzig TE, Zinzani PL, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017 Oct;92(10):E575-E583. Epub 2017 Aug 28. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.24854/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28699256 PubMed]
# Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009 May;145(3):344-9. Epub 2009 Feb 24. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07626.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19245430 PubMed]
# '''NHL-003:''' Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011 Jul;22(7):1622-7. Epub 2011 Jan 12. [http://annonc.oxfordjournals.org/content/22/7/1622.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21228334 PubMed]
## '''Update:''' Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, Tilly H, Zhang L, Prandi K, Li J, Witzig TE. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013 Nov;24(11):2892-7. Epub 2013 Sep 12. [http://annonc.oxfordjournals.org/content/24/11/2892.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811905/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24030098 PubMed]
## '''Pooled Update:''' Witzig TE, Zinzani PL, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017 Oct;92(10):E575-E583. Epub 2017 Aug 28. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.24854/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28699256 PubMed]
# Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH, Rule SA. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012 Oct;159(2):154-63. Epub 2012 Aug 9. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12008/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22881386 PubMed]
<!-- Presented in part at the 54th American Society of Hematology Meeting and Exposition, Atlanta, GA, December 8-11, 2012. -->
# '''EMERGE:''' Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013 Oct 10;31(29):3688-95. Epub 2013 Sep 3. [http://jco.ascopubs.org/content/31/29/3688.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879693/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24002500 PubMed]
## '''Update:''' Goy A, Kalayoglu Besisik S, Drach J, Ramchandren R, Robertson MJ, Avivi I, Rowe JM, Herbrecht R, Van Hoof A, Zhang L, Cicero S, Fu T, Witzig T. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015 Aug;170(4):496-503. Epub 2015 Apr 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13456/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029780/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25921098 PubMed]
## '''Pooled Update:''' Witzig TE, Zinzani PL, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017 Oct;92(10):E575-E583. Epub 2017 Aug 28. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.24854/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28699256 PubMed]
<!-- # '''Abstract:''' Marek Trneny, Thierry Lamy, Jan Walewski, Wojciech Jurczak, David Belada, MD, Jiri Mayer, Prof., MD, Ph.D., John Radford, Julia Alexeeva, Dzhelil Osmanov, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo and Luca Arcaini. Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study. ASH Annual Meeting 2014 Abstract 627 [https://ash.confex.com/ash/2014/webprogram/Paper69212.html link to abstract] -->
# '''SPRINT:''' Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczkowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo MC, Arcaini L; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016 Mar;17(3):319-31. Epub 2016 Feb 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00559-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26899778 PubMed]

==R-FCM {{#subobject:4f239|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-FCM: '''<u>R</u>'''ituximab, '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''itoxantrone

===Regimen {{#subobject:b06ce3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|[[#FCM|FCM]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day -1 (the day before FCM)
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 3
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 3
*[[Mitoxantrone (Novantrone)]] 8 mg/m<sup>2</sup> IV over 30 minutes once on day 1

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*PR/CR: [[#Rituximab_monotherapy_2|Rituximab maintenance]] versus [[#Observation_3|no further treatment]]

===References===
# Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. [http://www.bloodjournal.org/content/104/10/3064.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15284112 PubMed]
## '''Update:''' Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. [http://www.bloodjournal.org/content/108/13/4003.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16946304 PubMed]

==Temsirolimus monotherapy {{#subobject:575bde|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:273d39|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://jco.ascopubs.org/content/27/23/3822.long Hess et al. 2009]
|style="background-color:#1a9851"|Phase III (E)
|1. Investigator's choice<br> 2. Temsirolimus 175/25
|style="background-color:#1a9850"|Superior PFS
|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00667-4/fulltext Dreyling et al. 2015 (RAY)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Ibrutinib_monotherapy|Ibrutinib]]
|style="background-color:#d73027"|Inferior PFS
|style="background-color:#d73027"|Worse HRQoL
|-
|}
''The most commonly compared regimens in Hess et al. 2009 were single agent gemcitabine and single agent fludarabine.''
====Chemotherapy====
*[[Temsirolimus (Torisel)]] as follows:
**Cycle 1: 175 mg IV over 30 to 60 minutes once per day on days 1, 8, 15
**Cycle 2 onwards: 75 mg IV over 30 to 60 minutes once per day on days 1, 8, 15

====Supportive medications====
*[[:Category:Antihistamines|Antihistamine]] once 30 minutes prior to [[Temsirolimus (Torisel)]].
*Corticosteroid use was not allowed in Hess et al. 2009.

'''21-day cycles'''

===Variant #2 {{#subobject:503d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627208/ Ansell et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Temsirolimus (Torisel)]] 25 mg in 250 mL normal saline IV over 30 minutes once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg IV once prior to [[Temsirolimus (Torisel)]]

'''28-day cycle, stopped at various timepoints (see paper for details); maximum of 12 months'''

===Variant #3 {{#subobject:ec06c7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/23/5347.long Witzig et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Temsirolimus (Torisel)]] 250 mg in 250 mL normal saline IV over 30 minutes once per day on days 1, 8, 15, 22

====Supportive medications====
*Use of white blood cell growth factors at physician discretion if neutropenia occurred.
*Use of erythropoietin for anemia was allowed.

'''28-day cycles, given until progression, 2 cycles past CR, up to a total of 12 months'''

===References===
# Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10;23(23):5347-56. Epub 2005 Jun 27. [http://jco.ascopubs.org/content/23/23/5347.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15983389 PubMed]
# Ansell SM, Inwards DJ, Rowland KM Jr, Flynn PJ, Morton RF, Moore DF Jr, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008 Aug 1;113(3):508-14. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23580/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627208/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18543327 PubMed]
# Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Aug 10;27(23):3822-9. Epub 2009 Jul 6. [http://jco.ascopubs.org/content/27/23/3822.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19581539 PubMed]
# '''RAY:''' Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016 Feb 20;387(10020):770-8. Epub 2015 Dec 4. Erratum in: Lancet. 2016 Feb 20;387(10020):750.[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00667-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26673811 PubMed]
## '''HRQoL analysis:''' Hess G, Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Caballero D, Joao C, Witzens-Harig M, Bence-Bruckler I, Cho SG, Zhou W, Goldberg JD, Trambitas C, Enny C, Vermeulen J, Traina S, Chiou CF, Diels J, Dreyling M. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leuk Lymphoma. 2017 Dec;58(12):2824-2832. Epub 2017 May 30. [https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1326034 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28556689 PubMed]
## '''Update:''' Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018 Aug;32(8):1799-1803. Epub 2018 Feb 2. [https://www.nature.com/articles/s41375-018-0023-2 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087720/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29572505 PubMed]

=Relapsed or refractory, non-randomized or retrospective data=

==Acalabrutinib monotherapy {{#subobject:548dbb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:32f303|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33108-2/fulltext Wang et al. 2017 (ACE-LY-004)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 81% (95% CI: 73-87)
|-
|}
====Chemotherapy====
*[[Acalabrutinib (Calquence)]] 100 mg PO twice per day

'''Continued indefinitely'''

===References===
# '''ACE-LY-004:''' Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018 Feb 17;391(10121):659-667. Epub 2017 Dec 11. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33108-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29241979 PubMed]

==Arsenic trioxide & Chlorambucil {{#subobject:1edb5c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:c6220a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/25/7/1391.full.html Gill et al. 2014]
|style="background-color:#91cf61"|Phase II
|ORR: 49%
|-
|}
====Chemotherapy====
*[[Arsenic trioxide (Trisenox)]] 10 mg PO once per day, reduced to 5 mg PO once per day after 4 weeks
*[[Chlorambucil (Leukeran)]] 4 mg PO once per day, increased to 8 mg PO once per day if leukocyte count allowed

====Supportive medications====
*[[Ascorbic acid (Vitamin C)]] 1000 mg PO once per day

'''6-week course'''
====Subsequent treatment====
*Patients with at least SD: [[#Arsenic_trioxide_.26_Chlorambucil_2|Arsenic trioxide & chlorambucil maintenance]]

===References===
# Gill H, Au WY, Cheung WW, Lee EY, Kwong YL. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol. 2014 Jul;25(7):1391-7. Epub 2014 Apr 12. [http://annonc.oxfordjournals.org/content/25/7/1391.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24728036 PubMed]

==BeRT {{#subobject:37c30e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BeRT: '''<u>Be</u>'''ndamustine, '''<u>R</u>'''ituximab, '''<u>T</u>'''emsirolimus

===Regimen {{#subobject:f424c7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/leu/journal/v29/n8/full/leu201560a.html Hess et al. 2015]
|style="background-color:#ffffbe"|Phase I/II, <20 pts reported
|-
|}

''The temsirolimus dose was the maximum dose used in the phase I portion of the trial; no DLT were observed.''
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Temsirolimus (Torisel)]] 75 mg IV once per day on days 1, 8, 15

'''28-day cycle for up to 4 cycles'''

===References===
# Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015 Aug;29(8):1695-701. Epub 2015 Mar 13. [https://www.nature.com/leu/journal/v29/n8/full/leu201560a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25765545 PubMed]

==BDR {{#subobject:d29ebe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BDR: '''<u>B</u>'''ortezomib, '''<u>D</u>'''examethasone, '''<u>R</u>'''ituximab
<br>BORID: '''<u>BO</u>'''rtezomib, '''<u>RI</u>'''tuximab, '''<u>D</u>'''examethasone

===Regimen {{#subobject:36635a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128220/ Lamm et al. 2011]
|style="background-color:#ffffbe"|Phase II, <20 pts reported
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV over 3 to 5 seconds once per day on days 1, 4, 8, 11
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*Responding patients: [[#Rituximab_monotherapy_2|Rituximab consolidation]]

===References===
# Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011 Jul;96(7):1008-14. Epub 2011 Apr 12. [http://www.haematologica.org/content/96/7/1008.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128220/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21486866 PubMed]

==Bortezomib monotherapy {{#subobject:3bc0e1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, 1.3 mg/m<sup>2</sup> {{#subobject:c484ca|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/30/4867.long Fisher et al. 2006 (PINNACLE)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

'''21-day cycles''' "up to 17 cycles or four cycles beyond initial reporting of CR/CRu, discontinuing for progressive disease (PD) or unacceptable toxicity, or by patient/investigator decision."

===Variant #2, 1.5 mg/m<sup>2</sup> {{#subobject:9dff83|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/4/676.long O'Connor et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 pts reported
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

====Supportive medications====
*"Use of antiemetics, erythropoietin, and [[Filgrastim (Neupogen)]] was allowed if deemed necessary by the treating physician."

'''21-day cycles''' 

===References===
# O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005 Feb 1;23(4):676-84. Epub 2004 Dec 21. [http://jco.ascopubs.org/content/23/4/676.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15613699 PubMed]
# '''PINNACLE:''' Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006 Oct 20;24(30):4867-74. Epub 2006 Sep 25. [http://jco.ascopubs.org/content/24/30/4867.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17001068 PubMed] 
## '''Update:''' Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009 Mar;20(3):520-5. Epub 2008 Dec 12. [http://annonc.oxfordjournals.org/content/20/3/520.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592328/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19074748 PubMed]

==Cladribine monotherapy {{#subobject:340f61|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:50be81|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465670/ Inwards et al. 2008 (NCCTG 95-80-53)]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|}
====Chemotherapy====
*[[Cladribine (Leustatin)]] 5 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 5 

'''28-day cycle for up to 6 cycles'''

===References===
# Inwards DJ, Fishkin PA, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Veeder MH, Witzig TE. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008 Jul 1;113(1):108-16. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23537/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465670/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18470909 PubMed]

==Everolimus monotherapy {{#subobject:ae5164|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:de05a7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396682/ Renner et al. 2012 (SAKK 36/06)]
|style="background-color:#91cf61"|Phase II
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12780/full Wang et al. 2014 (PILLAR-1)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day in a fasting state or with a light fat-free meal

'''28-day cycles'''

===References===
# Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N; Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012 Jul;97(7):1085-91. Epub 2012 Feb 7. [http://www.haematologica.org/content/97/7/1085.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396682/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22315486 PubMed]
# Wang M, Popplewell LL, Collins RH Jr, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014 May;165(4):510-8. Epub 2014 Mar 2. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12780/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24579926 PubMed]

==Ibrutinib & Rituximab {{#subobject:5c125a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2b53b7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00438-6/fulltext Wang et al. 2015]
|style="background-color:#91cf61"|Phase II
| style="background-color:#f7fcfd" |ORR: 88% (95% CI 76-95.5)
|-
|}
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 560 mg PO once per day
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
**Cycle 2: no rituximab
**Cycles 3 to 8: 375 mg/m<sup>2</sup> IV once on day 1
**Cycle 10 onwards: 375 mg/m<sup>2</sup> IV once on day 1 of every other cycle, up to 2 years

'''28-day cycles'''

===References===
<!-- # '''Abstract:''' Michael (Luhua) Wang, MD, Fredrick Hagemeister, MD, Jason R. Westin, MD, Luis Fayad, MD, Felipe Samaniego, MD, Francesco Turturro, MD, Wendy Chen, Liang Zhang, MD, PhD, Maria Badillo, BS, Maria DeLa Rosa, Alicia Addison, Larry W. Kwak, MD, PhD and Jorge E. Romaguera, MD. Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. ASH Annual Meeting 2014 Abstract 627 [https://ash.confex.com/ash/2014/webprogram/Paper69685.html link to abstract] -->
# Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan;17(1):48-56. Epub 2015 Nov 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00438-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26640039 PubMed]

==Ibrutinib & Venetoclax {{#subobject:b479ff|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1aa538|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1715519 Tam et al. 2018 (AIM)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#bfd3e6" |ORR: 71% (95% CI 49-87)
|-
|}
''Note: the venetoclax dosing is based on a mid-protocol amendment.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 560 mg PO once per day
*[[Venetoclax (Venclexta)]] as follows:
**Week 5: 50 mg PO once per day
**Week 6: 100 mg PO once per day
**Week 7: 200 mg PO once per day
**Weeks 8 to 15: 400 mg PO once per day
**Week 16 onwards:
***CR achieved: 400 mg PO once per day
***CR not achieved: 800 mg PO once per day

'''Continued indefinitely'''

===References===
# '''AIM:''' Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-1223. [https://www.nejm.org/doi/full/10.1056/NEJMoa1715519 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29590547 PubMed]

==Lenalidomide & Rituximab {{#subobject:c6d2a9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 10/375 {{#subobject:1c4391|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/21/8/1835.full Chong et al. 2015]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week x 4 doses, given during the 3rd cycle

'''28-day cycles'''

===Variant #2, 25/375 {{#subobject:cd071c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70200-0/fulltext Wang et al. 2012]
|style="background-color:#91cf61"|Phase I/II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1 only: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''28-day cycles'''

===References===
# Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul;13(7):716-23. Epub 2012 Jun 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70200-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22677155 PubMed]
# Chong EA, Ahmadi T, Aqui NA, Svoboda J, Nasta SD, Mato AR, Walsh KM, Schuster SJ. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. Clin Cancer Res. 2015 Apr 15;21(8):1835-42. Epub 2015 Jan 28. [http://clincancerres.aacrjournals.org/content/21/8/1835.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25632047 PubMed]

==Obinutuzumab monotherapy {{#subobject:7f1090|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d640e0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/119/22/5126.long Salles et al. 2012 (GAUGUIN)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: this is the phase II dosing used in the subgroup analysis by Morschhauser et al. 2013.''
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 1600 mg (diluted to 10 mg/mL) IV once per day on days 1 & 8
**Cycles 2 to 8: 800 mg IV once on day 1
**Initial infusion rate is 50 mg/hour. In the absence of infusion-related reactions (IRRs), the rate is then increased by 50 mg/hour every 30 minutes, up to a maximum of 400 mg/hour.

====Supportive medications====
*[[Acetaminophen (Tylenol)]] or paracetamol 650 to 1000 mg PO once 30 minutes prior to [[Obinutuzumab (Gazyva)]]
*[[:Category:Antihistamines|An antihistamine]] 30 minutes prior to [[Obinutuzumab (Gazyva)]]; if there were no infusion-related reactions (IRRs) requiring medication or infusion interruption, antihistamine could be omitted for subsequent infusions
*Premedication with [[:Category:Steroids|corticosteroids]] recommended for patients at high risk of infusion-related reactions (IRRs)
*Use of [[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] allowed for severe neutropenia
*Antibiotic prophylaxis allowed

'''21-day cycle for 8 cycles'''

===References===
# '''GAUGUIN:''' Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012 May 31;119(22):5126-32. Epub 2012 Mar 19. [http://www.bloodjournal.org/content/119/22/5126.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22431570 PubMed]
## '''Subgroup analysis:''' Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2912-9. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/23/2912.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835718 PubMed]
## '''Subgroup analysis:''' Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2920-6. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/23/2920.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835715 PubMed]
## '''Subgroup analysis:''' Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014 Oct 2;124(14):2196-202. Epub 2014 Aug 20. [http://www.bloodjournal.org/content/124/14/2196 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25143487 PubMed]

==PEP-C {{#subobject:e8f271|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PEP-C: '''<u>P</u>'''rednisone, '''<u>E</u>'''toposide, '''<u>P</u>'''rocarbazine, '''<u>C</u>'''yclophosphamide

===Regimen {{#subobject:3bb8f7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.1080/10428190701837330 Coleman et al. 2008]
|style="background-color:#91cf61"|Non-randomized
|-
|}

====Induction phase====
*[[Prednisone (Sterapred)]] 20 mg PO once per day after breakfast
*[[Etoposide (Vepesid)]] 50 mg PO once per day after dinner
*[[Procarbazine (Matulane)]] 50 mg PO once per day at bedtime
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day after lunch

====Supportive medications====
*[[Ondansetron (Zofran)]] (dose not specified) with each [[Procarbazine (Matulane)]] dose

'''Continue until WBC count less than 3 x 10<sup>9</sup>/L, hold until WBC count recovery, then titrate in maintenance phase per paper (see publication for details)'''

====Maintenance phase====
*Same medications and doses given per day as used in the induction phase, but the number of days per week they are used is titrated to maintain a WBC count of at least 3; for example, 5 out of 7 days, every other day, once per week, etc.

===References===
# Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008 Mar;49(3):447-50. [https://www.tandfonline.com/doi/full/10.1080/10428190701837330 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18297520 PubMed]

==R-BL {{#subobject:82e685|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-BL: '''<u>R</u>'''ituximab, '''<u>B</u>'''endamustine, '''<u>L</u>'''enalidomide
<br>R2B: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>R</u>'''ituximab, '''<u>B</u>'''endamustine
===Regimen {{#subobject:1c30ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477625/ Zaja et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
*Cycle 1: 375 mg/m<sup>2</sup> IV once on day 8
*Cycles 2 to 4: 375 mg/m<sup>2</sup> IV once on day 1
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 2 & 3
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 14

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*Patients with PR/CR: [[#Lenalidomide_.26_Rituximab_4|Lenalidomide & rituximab consolidation]]

===References===
# Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017 May;102(5):e203-e206. Epub 2017 Jan 12. [http://www.haematologica.org/content/102/5/e203.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477625/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28082342 PubMed]

==RT-PEPC {{#subobject:bc6d27|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT-PEPC: '''<u>R</u>'''ituximab, '''<u>T</u>'''halidomide, '''<u>P</u>'''rednisone, '''<u>E</u>'''toposide, '''<u>P</u>'''rocarbazine, '''<u>C</u>'''yclophosphamide

===Regimen {{#subobject:ed397d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004744/ Ruan et al. 2010]
|style="background-color:#91cf61"|Non-randomized
|-
|}

====Induction phase====
*[[Rituximab (Rituxan)]] (dose not specified) IV once per week on weeks 1 to 4 of month 1
*[[Thalidomide (Thalomid)]] 50 mg PO once per day during months 1 & 2, then 100 mg PO once per day for month 3
*[[Prednisone (Sterapred)]] 20 mg PO once per day after breakfast
*[[Etoposide (Vepesid)]] 50 mg PO once per day after dinner
*[[Procarbazine (Matulane)]] 50 mg PO once per day at bedtime
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day after lunch

====Supportive medications====
*[[Aspirin]] 81 mg PO once per day "after 2 episodes of DVT occurred."

'''3-month course'''

====Maintenance phase====
*[[Rituximab (Rituxan)]] (dose not specified) IV once per week on weeks 1 to 4 every 4 months
*[[Thalidomide (Thalomid)]] 100 mg PO once per day
*PEPC: Same medications and doses given per day as used in the induction phase, but titrated to maintain ANC of at least 2000/uL.

====Supportive medications====
*[[Aspirin]] 81 mg PO once per day "after 2 episodes of DVT occurred."

'''Continued indefinitely'''

===References===
# Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010 Jun 1;116(11):2655-64. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25055/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004744/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20235190 PubMed]

==Temsirolimus & Rituximab {{#subobject:8a89c9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8fb4aa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70062-6/fulltext Ansell et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Temsirolimus (Torisel)]] 25 mg IV once per week on weeks 1 to 4
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week on weeks 1 to 4 of cycle 1, then once on day 1 of every other cycle (cycles 3, 5, 7, 9, 11)

'''28-day cycle up to 12 cycles'''

===References===
# Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011 Apr;12(4):361-8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70062-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106222/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21440503 PubMed]

==VR {{#subobject:ea40ed|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VR: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''ituximab

===Regimen {{#subobject:4421a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116936/ Baiocchi et al. 2011]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|}
''Bortezomib dose was initially 1.5 mg/m<sup>2</sup> but was reduced due to excess grade 3 neurotoxicity.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Rituximab (Rituxan)]] as follows:
**Cycles 2 to 5: 375 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for up to 5 cycles'''

====Subsequent treatment====
*SD or better: Optional [[#VR_2|VR maintenance]]

===References===
# Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011 Jun 1;117(11):2442-51. Epub 2010 Dec 14. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25792/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116936/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24048792 PubMed]

=Consolidation after second-line therapy=

==BFR, then allo HSCT {{#subobject:c2659b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BFR: '''<u>B</u>'''endamustine, '''<u>F</u>'''ludarabine, '''<u>R</u>'''ituximab
===Regimen {{#subobject:41fd04|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260365/ Khouri et al. 2014]
| style="background-color:#ffffbe" |Phase II, <20 pts in this subgroup
|-
|}
{{#lst:Allogeneic HSCT|41fd04}}
===References===
# Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL Jr, Gulbis A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014 Oct 2;124(14):2306-12. Epub 2014 Aug 21. [http://www.bloodjournal.org/content/124/14/2306.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260365/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25145344 PubMed]

==FluBuCy, then allo HSCT {{#subobject:84acb0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FluBuCy: '''<u>Flu</u>'''darabine, '''<u>Bu</u>'''sulfan, '''<u>Cy</u>'''clophosphamide
===Regimen {{#subobject:bfe434|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70161-5/fulltext Glass et al. 2014 (DSHNHL R3)]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|bfe434}}
===References===
<!-- # Glass B, rabbits Kamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N. High-dose chemotherapy Followed by allogeneic stem cell transplantation in relapsed and refractory high-risk aggressive non-Hodgkin's lymphoma: Results of a prospective study of the German high-grade non-Hodgkin's lymphoma study group. J Clin Oncol 30, 2012 (suppl; abstr 8004) -->
# '''DSHNHL R3:''' Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N; on behalf of the German High-Grade Lymphoma Study Group. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014 Jun;15(7):757-66. Epub 2014 May 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70161-5/fulltext link to original article] [http://www.dshnhl.org/app/download/9495510598/Studienprotokoll+DSHNHL+alloFBC+final+vollst.pdf link to original protocol (in German)] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827808 PubMed]

==Lenalidomide & Rituximab {{#subobject:3d8123|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b59073|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477625/ Zaja et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-BL|R2B]] x 4
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*Patients with a continued PR/CR: [[#Lenalidomide_monotherapy_2|Lenalidomide maintenance]]

===References===
# Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017 May;102(5):e203-e206. Epub 2017 Jan 12. [http://www.haematologica.org/content/102/5/e203.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477625/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28082342 PubMed]

=Maintenance after second-line therapy=

==Arsenic trioxide & Chlorambucil {{#subobject:8e11ec|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:6837fa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/25/7/1391.full.html Gill et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Arsenic_trioxide_.26_Chlorambucil|Arsenic trioxide & Chlorambucil]] x 6 wk
====Chemotherapy====
*[[Arsenic trioxide (Trisenox)]] 3 mg PO once per day
*[[Chlorambucil (Leukeran)]] 2 mg PO once per day

====Supportive medications====
*[[Ascorbic acid (Vitamin C)]] 300 mg PO once per day

'''Continued indefinitely'''

===References===
# Gill H, Au WY, Cheung WW, Lee EY, Kwong YL. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol. 2014 Jul;25(7):1391-7. Epub 2014 Apr 12. [http://annonc.oxfordjournals.org/content/25/7/1391.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24728036 PubMed]

==Lenalidomide monotherapy {{#subobject:f4a26c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 15 mg 21/28, 18 months {{#subobject:f90ac2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477625/ Zaja et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Lenalidomide_.26_Rituximab_4|Lenalidomide & Rituximab]] x 2
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21

'''28-day cycle for up to 18 months'''

===Variant #2, 15 mg 21/28, indefinite {{#subobject:7c3cfe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12008/full Eve et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Lenalidomide_monotherapy|Lenalidomide]] x 6
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21 

'''28-day cycles'''

===References===
# Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH, Rule SA. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012 Oct;159(2):154-63. Epub 2012 Aug 9. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12008/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22881386 PubMed]
# Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017 May;102(5):e203-e206. Epub 2017 Jan 12. [http://www.haematologica.org/content/102/5/e203.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477625/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28082342 PubMed]

==Observation {{#subobject:7600b6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:0336ab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_2|Rituximab]]
|style="background-color:#fc8d59"|Seems to have inferior response duration
|-
|}
====Preceding treatment====
*[[#FCM|FCM]] x 4 versus [[#R-FCM|R-FCM]] x 4

''No further treatment was given.''

===References===
# Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. [http://www.bloodjournal.org/content/104/10/3064.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15284112 PubMed]
## '''Update:''' Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. [http://www.bloodjournal.org/content/108/13/4003.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16946304 PubMed]

==Rituximab monotherapy {{#subobject:ea4966|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:6875f6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/104/10/3064.long Forstpointner et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_3|Observation]]
|style="background-color:#91cf60"|Seems to have superior response duration
|-
|}
====Preceding treatment====
*[[#FCM|FCM]] x 4 versus [[#R-FCM|R-FCM]] x 4, followed in 3 months by:
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week on days 1, 8, 15, 22

'''3-month cycle for two cycles'''

===Variant #2 {{#subobject:607ae6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128220/ Lamm et al. 2011]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|}
====Preceding treatment====
*[[#BDR|BORID]] x 6
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 8 weeks

'''4 doses'''

===References===
# Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. [http://www.bloodjournal.org/content/104/10/3064.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15284112 PubMed]
## '''Update:''' Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. [http://www.bloodjournal.org/content/108/13/4003.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16946304 PubMed]
# Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011 Jul;96(7):1008-14. Epub 2011 Apr 12. [http://www.haematologica.org/content/96/7/1008.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128220/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21486866 PubMed]

==VR {{#subobject:465914|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VR: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''ituximab

===Regimen {{#subobject:67cd8d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116936/ Baiocchi et al. 2011]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|}
====Preceding treatment====
*[[#VR|VR]] x 5
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per week for two weeks
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week for four weeks

'''6-month cycle for up to 2 years'''

===References===
# Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011 Jun 1;117(11):2442-51. Epub 2010 Dec 14. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25792/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116936/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24048792 PubMed]

=Investigational agents=
''These are drugs under study with at least some promising results for this disease.''

*[[Abexinostat (PCI-24781)]]
*[[Alisertib (MLN8237)]]

=Prognosis=

==Mantle cell lymphoma international prognostic index (MIPI)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

Calculation generally require a calculator such as the one provided by [http://bloodref.com/lymphoid/lymphoma/mipi BloodRef]. The MIPI is calculated using the following formula: [0.03535 × age (in years)] + 0.6978 (if ECOG PS greater than 1) + [1.367 × log<sub>10</sub>(LDH/ULN)] + [0.9393 × log<sub>10</sub>(white cells per uL blood)]. Risk factors include:

*Age
*[[#ECOG_performance_status_.28WHO.2FZubrod_score.29|ECOG Performance Status]]
*Serum LDH level (''note that reference ranges can vary widely!'')
*Number of nodal sites
*WBC count

Risk stratification:
*'''Less than 5.7 points''': Low risk
*'''5.7 to less than 6.2 points''': Intermediate risk
*'''Greater than or equal to 6.2 points''': High risk

===References===
# Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65. Epub 2007 Oct 25. Erratum in: Blood. 2008 Jun 15;111(12):5761. [http://www.bloodjournal.org/content/111/2/558.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17962512 PubMed]
# Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338-46. Epub 2014 Mar 31. [http://jco.ascopubs.org/content/32/13/1338.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24687837 PubMed]

=Response criteria=
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979083/ Lugano Classification criteria (2014)] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979083/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25113753 PubMed]
*[http://jco.ascopubs.org/content/17/4/1244.long NCI Sponsored International Working Group criteria (1999)] [https://www.ncbi.nlm.nih.gov/pubmed/10561185 PubMed]

[[Category:Mantle cell lymphoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Aggressive lymphomas]]
